2 Under-the-Radar Stocks to Buy Heading Into 2026

These drugmakers are poised to profit from their innovative engines.Axsome Therapeutics (AXSM 1.63%) and Exelixis (EXEL 1.70%) are hardly the best-known players in the large biotech industry. Thankfully, they don't need to be so to have excellent prospects. Both of these relatively small drugmakers have a lot going on that could lead to excellent financial results and strong stock market performances in the medium term. Let's dig deeper into Axsome Therapeutics and Exelixis and discuss why both biotechs are ...